Precis Future Med.  2024 Mar;8(1):23-27. 10.23838/pfm.2023.00170.

Durable response to first-line treatment with AZD3759 (zorifertinib) in a patient with epithelial growth factor receptor mutated non-small cell lung cancer and untreated multiple brain metastasis

• Lee J
• Ahn MJ
• Park S

• KMID: 2553873
• DOI: http://doi.org/10.23838/pfm.2023.00170

Abstract

Central nervous system (CNS) metastases, including brain and leptomeningeal metastasis, are associated with poor prognosis in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients. CNS metastasis occurs in more than 50% of EGFR-mutated NSCLC cases during the treatment course. The treatment options for CNS metastases in these patients are limited, and there have been ongoing efforts to develop targeted agents with enhanced CNS penetration. AZD3759 (zorifertinib) is a novel EGFR tyrosine kinase inhibitor with a high capability of CNS penetration and proven efficacy with tolerable safety profiles. In this report, we describe a case of a patient with EGFR-mutant NSCLC that was initially diagnosed with multiple brain metastasis who demonstrated prolonged response of both intra- and extracranial lesions over 7 years with AZD3759 as first-line treatment.

Keyword

AZD3759; Brain metastasis; EGFR-TKI; Non-small-cell lung cancer